Apart from the direct effect on immune and tumor cells, surprisingly, the application of the VEGF-A inhibiting antibody bevacizumab to R-CHOP therapy increased adverse cardiac events, yet without increasing the therapeutic efficacy in DLBCL patients (214, 215). The gene discussed is VEGFA; the disease is neoplasm.